A new survey of cancer doctors published in a research note from investment bank R.W. Baird provides some more reasons for investors to worry about Dendreon and its prostate cancer treatment Provenge, ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Much has been said and written about the circumstances surrounding the launch of Dendreon’s innovation in cancer treatment, Provenge, a novel immunotherapeutic treatment for end-stage prostate cancer.

One of the first big stories I wrote about at Forbes was the controversy over embryonic stem cells that raged in 2000 and 2001 and resulted in a major compromise announced by President Bush ten years ...

Four months. It may not seem like a long time to many people, but for those with cancer, it's 120 days they might not have. A breakthrough treatment for prostate cancer patients is changing that for ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

Shares of Dendreon surged Thursday after the company said sales of its prostate-cancer therapy Provenge continued to grow in the fourth quarter. Seattle-based Dendreon said sales of Provenge rose to ...

April 19, 2011 — The days when the Centers for Medicare and Medicaid Services (CMS) cannot negotiate payment with drug makers over pricey drugs in Medicare Part B, especially cancer drugs, will come ...

Since its launch in 2010, investors have been waiting for Dendreon's ($DNDN) prostate cancer vaccine Provenge to get some traction in the U.S. market. But instead of ...

Two cancer doctors have received threatening e-mails in recent weeks because of their opposition to Provenge, an experimental prostate-cancer drug developed by Seattle-based Dendreon. The doctors, ...

Dublin, April 30, 2026 (GLOBE NEWSWIRE)-- The "Provenge Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...